Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited Fundamental Analysis
Jacobson Pharma Corporation Limited (2633.HK) shows moderate financial fundamentals with a PE ratio of 8.25, profit margin of 19.73%, and ROE of 12.91%. The company generates $1.5B in annual revenue with moderate year-over-year growth of 7.43%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 58.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 2633.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2633.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2633.HK trades at attractive valuation levels.
Growth Score
Moderate2633.HK shows steady but slowing expansion.
Financial Health Score
Excellent2633.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate2633.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 2633.HK Expensive or Cheap?
P/E Ratio
2633.HK trades at 8.25 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2633.HK's PEG of 0.08 indicates potential undervaluation.
Price to Book
The market values Jacobson Pharma Corporation Limited at 1.12 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.61 times EBITDA. This is generally considered low.
How Well Does 2633.HK Make Money?
Net Profit Margin
For every $100 in sales, Jacobson Pharma Corporation Limited keeps $19.73 as profit after all expenses.
Operating Margin
Core operations generate 22.91 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.91 in profit for every $100 of shareholder equity.
ROA
Jacobson Pharma Corporation Limited generates $8.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Jacobson Pharma Corporation Limited generates strong operating cash flow of $496.94M, reflecting robust business health.
Free Cash Flow
Jacobson Pharma Corporation Limited generates strong free cash flow of $269.60M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.13 in free cash annually.
FCF Yield
2633.HK converts 10.76% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
8.25
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.12
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.63
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.40
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.41
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How 2633.HK Stacks Against Its Sector Peers
| Metric | 2633.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 8.25 | 28.45 | Better (Cheaper) |
| ROE | 12.91% | 763.00% | Weak |
| Net Margin | 19.73% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.40 | 0.34 | Neutral |
| Current Ratio | 1.41 | 2795.60 | Neutral |
| ROA | 8.58% | -16588.00% (disorted) | Weak |
2633.HK outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Jacobson Pharma Corporation Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.20%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
39.31%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
40.05%
Industry Style: Defensive, Growth, Innovation
High Growth